5 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital
In this article, we discuss 5 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.
Foghorn Therapeutics Inc. (FHTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Euclidean Capital Jim Simons | 1,573,761 | $10,559,936 | 1.35% | |
| 2. | Point72 Asset Management Steve Cohen | 437,369 | $2,934,746 | -20% | 0% |
| 3. | Birchview Capital Matthew Strobeck | 320,930 | $2,153,440 | 1.75% | |
| 4. | Driehaus Capital Richard Driehaus | 280,382 | $1,881,363 | -19% | 0.01% |
| 5. | Sio Capital Michael Castor | 121,672 | $816,419 | 0.24% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 5,500 | Officer | 258,397 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | Large Shareholder | 1,851,801 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | Large Shareholder | 1,491,441 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | Large Shareholder | 9,330,878 | 2020-10-27 | Filing | |
| $16.00 | 150,000 | 1,231,081 | 2020-10-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.56 | 11,000 | 75,992 | 2024-03-11 | Filing | ||
| $8.25 | 311,297 | 0 | 2023-08-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,674,120 | $81,748,073 | 6.16% | |
| 2. | 2,810,009 | $18,124,558 | 0% | |
| 3. | 2,068,387 | $13,341,096 | 0% | |
| 4. | 1,305,868 | $8,422,848 | 0% | |
| 5. | 1,025,113 | $6,611,979 | 0% |
News See All
5 Best Biotech and AI Stocks To Buy According To Billionaire Jim Simons
In this article, we discuss 5 stock picks of Jim Simons’ Euclidean Capital.
10 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we reviewed Jim Simons' investment strategy, historical performance, and family office portfolio.
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we will discuss the 11 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Billionaire Hedge Funds
